Peptic Patents (Class 514/927)
  • Patent number: 8513226
    Abstract: The present invention relates to preparation and biological evaluation of 3-acetoxy-17-acetamido-16-formyl-androst-5,17-diene (4) and 3-acetoxy2?-chloro-5-androsteno[17,16-b]pyridine (5) as gastric proton pump inhibitor and their comparison to that of omeprazole, a clinically employed anti-gastric ulcer drug. Compound (4) exhibited dose dependent inhibition of histamine-stimulated acid secretion in gastric parietal cell with an IC50 value comparable to cimetidine. No mortality or behavioral abnormality of Swiss albino mice was observed under single-dose level of 1 g/Kg body weight of compound (4). Compound (4) further exhibited excellent anti ulcer activity in vivo against indomethacin induced ulcer.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: August 20, 2013
    Assignee: Council of Scientific and Industrial Research
    Inventors: Romesh Chandra Boruah, Moyurima Borthakur, Madan Gopal Barthakur, Paruchuri Gangadhar Rao, Sudip Kumar Kar, Annalakshmi Chinniah, Suchandra Goswami, Pratap Kumar Das
  • Patent number: 8383690
    Abstract: The present invention deals with the pharmaceutical composition comprising the therapeutically effective amount of a compound oenothein C obtained from the bioactive fraction of plant Woodfordia fruticosa optionally along with one or more pharmaceutically acceptable carriers, additives, lubricants and diluents. Further it also provides a method of treating peptic ulcer diseases in a subject using the said pharmaceutical composition. It also relates to the use of the compound oenothein C in the treatment of peptic ulcer related diseases and a process for the isolation of the said compound.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: February 26, 2013
    Assignee: Council of Scientific and Industrial Research
    Inventors: Sukdeb Banerjee, Pratap K. Das, Suchandra Goswami, Annalakshmi Chinniah, Nilendu Panda, Niranjan Prasad Sahu, Basudeb Achari
  • Patent number: 8187614
    Abstract: Infectious diseases caused by pathogenic microorganisms resident in the alimentary tract of humans and animals can be prevented and treated by administering to the alimentary tract of the human or animal an effective amount of a composition containing at least one lectin capable of binding to an infective microorganism and diminishing its infective capability of the microorganism. The lectin is administered dispensed in a pharmaceutically acceptable non-toxic vehicle. Peptic ulcer disease caused by infection with H. pylori can be treated by oral administration of lectins that bind to the pathogen. A beneficial ecology of H. pylori can be maintained in infected patients by chronic oral administration of lectins that bind to the pathogen.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: May 29, 2012
    Assignee: Legere Pharmaceuticals, Ltd.
    Inventors: Howard C. Krivan, Richard C. Potter, Michael J. Oldham
  • Patent number: 7803574
    Abstract: This invention provides novel nanofiber enhanced surface area substrates and structures comprising such substrates for use in various medical devices, as well as methods and uses for such substrates and medical devices. In one particular embodiment, a method of administering a composition to a patient is disclosed which comprises providing a composition-eluting device, said composition-eluting device comprising at least a first surface and a plurality of nanostructures attached to the first surface, and introducing the composition-eluting device into the body of the patient.
    Type: Grant
    Filed: February 22, 2007
    Date of Patent: September 28, 2010
    Assignee: Nanosys, Inc.
    Inventors: Tejal Desai, R. Hugh Daniels, Vijendra Sahi
  • Patent number: 7790672
    Abstract: Infectious diseases caused by pathogenic microorganisms resident in the alimentary tract of humans and animals can be prevented and treated by administering to the alimentary tract of the human or animal an effective amount of a composition containing at least one lectin capable of binding to an infective microorganism and diminishing its infective capability of the microorganism. The lectin is administered dispensed in a pharmaceutically acceptable non-toxic vehicle. Peptic ulcer disease caused by infection with H. pylori can be treated by oral administration of lectins that bind to the pathogen. A beneficial ecology of H. pylori can be maintained in infected patients by chronic oral administration of lectins that bind to the pathogen.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: September 7, 2010
    Assignee: Legere Pharmaceuticals, Inc.
    Inventors: Howard C. Krivan, Richard C. Potter, Michael J. Oldham
  • Patent number: 7544710
    Abstract: The present invention relates to the use of the distrontium salt of 2-[N,N-di(carboxymethyl)amino]-3-cyano-4-carboxymethyl-thiophene-5-carboxylic acid in obtaining medicaments intended for the treatment of gastro-duodenal pain.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: June 9, 2009
    Assignee: Les Laboratoires Servier
    Inventor: Yannis Tsouderos
  • Patent number: 7351723
    Abstract: Lyophilized pantoprazole preparations which are obtainable by freeze-drying of an aqueous solution of pantoprazole, ethylenediamine tetraacetic acid and/or a suitable salt thereof, and sodium hydroxide and/or sodium carbonate are disclosed. The preparations have advantageous properties when reconstituted for injection.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: April 1, 2008
    Assignee: Nycomed GmbH
    Inventors: Rudolf Linder, Rango Dietrich
  • Patent number: 7291353
    Abstract: A pharmaceutical composition comprising an effective amount of an extract or lyophilized extract or at least one bioactive fraction obtained from the plant Woodfordia fruticosa along with one or more pharmaceutically acceptable additives/carriers for treating ulcer caused by the conditions such as stress induced ulcer, peptic ulcer, cold restraint induced ulcer, drug induced ulcer and acid induced ulcer, also used as specific inhibitor of gastric H+, K+-ATPase and anti-Helicobacter pylori activity.
    Type: Grant
    Filed: August 17, 2005
    Date of Patent: November 6, 2007
    Assignee: Council of Scientific and Industrial Research
    Inventors: Pratap K. Das, Niranjan P. Sahu, Sukdeb Banerjee, Suchandra Sett, Suchandra Goswami, Samir Bhattacharya
  • Patent number: 6949519
    Abstract: Azithromycin in the form of a monohydrate comprising from 4.0% to 6.5% of water, a process for its preparation and its use in pharmaceutical compositions.
    Type: Grant
    Filed: November 26, 2001
    Date of Patent: September 27, 2005
    Assignee: Sandoz AG
    Inventors: Victor Centellas, José Diago, Rafael Garcia, Johannes Ludescher
  • Patent number: 6855347
    Abstract: The present invention relates to a novel synergistic herbal composition for the treatment of gastric ulcer, a method for preparing said synergistic herbal composition and a process for the treatment of gastric ulcer using said composition and more particularly, the present invention relates to a novel synergistic herbal composition which is effective against pyloric ligation induced ulcer model and histamine induced ulcer model.
    Type: Grant
    Filed: March 25, 2002
    Date of Patent: February 15, 2005
    Assignee: Council of Scientific and Industrial Research
    Inventors: Janaswamy Madhusudana Rao, Upparapalli Sampathkumar, Boggavarapu Subrahmanya Sastry, Jhillu Singh Yadav, Kondapuram Vijaya Raghavan, Gautam Palit, Deepak Rai, Panniyampally Madhavankutty Varier, Trikovil Sankaran Muraleedharan, Kollath Muraleedharan
  • Patent number: 6780881
    Abstract: Lyophilized pantoprazole preparations which are obtainable by freeze-drying of an aqueous solution of pantoprazole, ethylenediamine tetraacetic acid and/or a suitable salt thereof, and sodium hydroxide and/or sodium carbonate are disclosed. The preparations have advantageous properties when reconstituted for injection.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: August 24, 2004
    Assignee: Altana Pharma AG
    Inventors: Rudolf Linder, Rango Dietrich
  • Patent number: 6767559
    Abstract: The present invention provides DASC compositions, which upon introduction into aqueous solutions, form stable, non-gritty suspensions. The present invention also provides stable, non-gritty suspensions comprising the DASC compositions of the present invention admixed in aqueous solutions. In addition, the present invention provides processes for preparing the suspensions which comprise admixing the DASC compositions of the present invention with aqueous solutions. Finally, the present invention provides processes for preparing the DASC compositions of the present invention.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: July 27, 2004
    Assignee: Chattem Chemicals, Inc.
    Inventors: Joel Swinson, Richard D. Giles, Jack Pitkin, Glenda Fleming, David B. Blum
  • Patent number: 6638523
    Abstract: A method of treating ulcers comprising administering an effective amount of carnosic acid and/or carnosol or a plant extract containing carnosic acid and/or carnosol as an effective ingredient to a subject having such ulcers.
    Type: Grant
    Filed: October 26, 2000
    Date of Patent: October 28, 2003
    Assignee: Nagase & Company, Ltd.
    Inventors: Toshitsugu Miyazaki, Kunio Kosaka, Hisatomi Ito
  • Patent number: 6593339
    Abstract: The present invention discloses a new use of NO-releasing NSAIDs, especially NO-releasing NSAIDs of the formula I, or a pharmaceutically acceptable salt or enantiomer thereof, for the manufacture of a medicament for the treatment of bacterial infections, especially caused or mediated by Helicobacter pylon. Disclosed is also the new use of a NO-releasing NSAID in combination with an acid susceptible proton pump inhibitor for the treatment of bacterial infections.
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: July 15, 2003
    Assignee: AstraZeneca AB
    Inventors: Arne Eek, Johan Raud
  • Patent number: 6555534
    Abstract: The use of 4,4-methylenebis (tetrahydro-1,2-4-thiadiazine-1,1 -dioxide) in the eradication and control of the microorganism Helicobacter pylori in humans is disclosed.
    Type: Grant
    Filed: March 10, 1999
    Date of Patent: April 29, 2003
    Assignee: Medpointe Healthcare Inc.
    Inventor: James C. Costin
  • Patent number: 6498171
    Abstract: Methods and compositions are disclosed utilizing hydroxyomeprazole for the treatment of ulcers in humans. Hydroxyomeprazole exhibits a lessened liability toward drug-drug interactions than omeprazole and a more predictable dosing regimen than omeprazole. Hydroxyomeprazole is also useful for the treatment of gastroesophageal reflux and other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
    Type: Grant
    Filed: August 10, 2001
    Date of Patent: December 24, 2002
    Assignee: Sepracor Inc.
    Inventors: William E. Yelle, Dean A. Handley
  • Patent number: 6489317
    Abstract: The invention provides methods for the treatment and/or prevention of recurrence of a gastrointestinal disorder associated with Helicobacter pylori in a patient requiring said treatment and/or prevention, which comprise administering to the patient a therapeutically effective amount of a first antibiotic which is an ansamycin and a therapeutically effective amount of at least a second antibiotic or antimicrobial agent. The invention also provides pharmaceutical compositions for use in the methods of the invention.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: December 3, 2002
    Inventor: Thomas Julius Borody
  • Patent number: 6479041
    Abstract: A method for producing aqueous emulsions or suspensions is described, in which a liquid phase is added to a supply tank, which is connected to a homogenizer having a stator, a rotor mounted rotatably in the stator and an additional connection, through which a second phase, which is to be homogenized, can be added directly onto the rotor and comes into contact with the previously added phase only in the toothed rings of the rotor, the homogenizer is started and subsequently the second phase, which is insoluble in the previously added phase and is to be homogenized, is supplied in liquid form through the additional connection. At least one of the two phases is an aqueous phase and at least one of the two phases is not heated.
    Type: Grant
    Filed: February 28, 2000
    Date of Patent: November 12, 2002
    Assignee: Wella Aktiengesellschaft
    Inventors: Rainer Huff, Gerd Frauenrieder, Bernhard Bieber
  • Patent number: 6471955
    Abstract: This invention provides a method of preparing a polymeric delivery system for active ingredients having enhanced site specific release performance characteristics. The delivery system is formed either by attaching the active ingredient to a linker through an acid-sensitive covalent bond, then forming a covalent bond between the linker and a portion of the subunits of a crosslinked polystyrene polymer, or by attaching a linker to a portion of the subunits of a crosslinked polystyrene polymer, then attaching the active ingredient to the polymer-linker combination through an acid-sensitive covalent bond. The invention also provides a delivery system comprising an active ingredient covalently bonded through an acid-sensitive covalent bond to a linker, which is in turn covalently bonded to a portion of subunits of a crosslinked polystyrene polymer.
    Type: Grant
    Filed: March 30, 1998
    Date of Patent: October 29, 2002
    Assignee: Pharmacia Corporation
    Inventors: Samuel J. Tremont, Denis Forster, Ricky L. Fenton, Yinong Ma
  • Patent number: 6444232
    Abstract: The present invention provides DASC compositions, which upon introduction into aqueous solutions, form stable, non-gritty suspensions. The present invention also provides stable, non-gritty suspensions comprising the DASC compositions of the present invention admixed in aqueous solutions. In addition, the present invention provides processes for preparing the suspensions which comprise admixing the DASC compositions of the present invention with aqueous solutions. Finally, the present invention provides processes for preparing the DASC compositions of the present invention.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: September 3, 2002
    Assignee: Chattem Chemicals, Inc.
    Inventors: Joel Swinson, Richard D. Giles, Jack Pitkin, Glenda Fleming, David B. Blum
  • Patent number: 6420436
    Abstract: This invention relates to a non-aqueous fluorocarbon composition for use in magnetic resonance imaging (MRI) or radiographic imaging (X-ray or computed tomography), particularly imaging of the gastrointestinal (GI) tract; an improved fluorocarbon composition with enhanced contrast effects in the GI tract; a fluorocarbon composition having improved palatability; a fluorocarbon composition for delivering drugs or bioactive agents; improved preparations for radiographic imaging or MRI; methods for producing and using such preparations; methods for improving the palatability of non-aqueous liquids; and methods for improving imaging.
    Type: Grant
    Filed: June 19, 1998
    Date of Patent: July 16, 2002
    Assignee: Alliance Pharmaceutical Corp.
    Inventor: W. Dean Kirkland
  • Patent number: 6420435
    Abstract: Methods of treating gastrointestinal disorders (e.g. heart bum, GERD, and gastric indigestion) comprising orally administering therapeutically effective amounts of limonene are described herein.
    Type: Grant
    Filed: October 12, 2000
    Date of Patent: July 16, 2002
    Inventor: Joe S. Wilkins, Jr.
  • Patent number: 6395307
    Abstract: An aqueous pourable liquid composition comprising a high concentration of sodium alginate and an alkali metal bicarbonate, wherein the sodium alginate has an average mannuronic acid residue to guluronic acid residue ratio of at least 0.6:1. In addition, an alginate or alginic acid for forming a protective coating on gastrointestinal mucosal tissue, use of and compositions including the same are provided.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: May 28, 2002
    Assignee: Reckitt Benckiser (UK) Limited
    Inventors: Douglas Banning, Peter William Dettmar, Ian Gordon Jolliffe, Frank Chadwick Hampson, Edvar Jarle Onsoyen, Paul Frederick Field, Duncan Quinell MacKenzie Craig, Ase Hanne Kristensen
  • Patent number: 6380234
    Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula wherein R1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R3 and R5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.
    Type: Grant
    Filed: August 8, 2001
    Date of Patent: April 30, 2002
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Tadashi Makino, Tetsuro Tabata, Shin-Ichiro Hirai
  • Patent number: 6379651
    Abstract: The invention relates to concomitant treatment with bismuth compounds, other antibacterial compounds, and/or antibiotics in oral-topical and peroral dosage forms to eradicate H. pylori from its niches both in the dental plaque and in the gastric mucosa in order to improve the ulcer cure rate and prevent ulcer relapse. The invention also provides oral topical dosage forms with pharmaceutically usable bismuth compounds, other antibacterial compounds, and/or antibiotics that eradicate or reduce H. pylori in dental plaque. The invention further provides for treatment with bismuth compounds, other antibacterial compounds, and/or antibiotics which are effective against Campylobacter rectus and Treponema denticola which are responsible for causing halitosis. The invention also provides bismuth compounds which have applications in wound healing, particularly in ocular and dermal wound healing.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: April 30, 2002
    Assignee: Josman Laboratories
    Inventor: Narayan Athanikar
  • Patent number: 6365201
    Abstract: A phytochemical composition for management of peptic ulcer conditions in humans is provided. The composition is a hot water extract of powdered Indigofera arrecta plant leaves. The extract may be prepared by contacting the powdered leaves with hot water for a period of time, filtering the extraction mixture, concentrating the filtrate in vacuo and freeze drying the concentrated filtrate. The extract is admixed with magnesium carbonate, dried maize starch, talc and magnesium stearate to form a homogenous mass which is filled into capsules. The capsules are ingested orally to provide an analgesic effect. Also described are methods for making the extract and the methodology for using the extract.
    Type: Grant
    Filed: June 29, 2000
    Date of Patent: April 2, 2002
    Assignee: National Institute for Pharmaceutical Research and Development
    Inventors: Charles O. N. Wambebe, Shingu K. Gamaniel, Peter Akah, Dogara S. Fumen, Hafsatu Shittu
  • Patent number: 6291517
    Abstract: A method is disclosed for preventing and/or reducing stress-induced gastric injury by administering an amount of grape seed proanthocyanidin extract effective to inhibit injury is administered to persons identified as among those with or at risk for such injury.
    Type: Grant
    Filed: November 19, 1999
    Date of Patent: September 18, 2001
    Assignee: Dry Creek Nutrition, Inc
    Inventors: Debasis Bagchi, Manashi Bagchi, Sidney J. Stohs
  • Patent number: 6258376
    Abstract: The invention provides a method of making a chewing gum composition containing a water soluble bulk portion, a water insoluble chewing gum base portion, a flavoring agent, and bismuth-containing compounds. The invention provides a method of making a bismuth-containing gum which when chewed multiple times per day, over the period of two weeks, is effective in reducing peptic ulcers by eradicating H. pylori. The chewing gum is also effective in eliminating forms of halitosis. The chewing gum does not have undesirable side effects, unpleasant taste and poor chewing characteristics.
    Type: Grant
    Filed: May 4, 1998
    Date of Patent: July 10, 2001
    Assignee: Josman Laboratories, Inc.
    Inventor: Narayan K. Athanikar
  • Patent number: 6147053
    Abstract: The invention relates to active substance combinations which consist of at least one polypeptide with the biological action of fibroblast growth factors and of at least one cationic polyelectrolyte. These combinations permit improved dosage of the FGF activity.
    Type: Grant
    Filed: November 24, 1998
    Date of Patent: November 14, 2000
    Assignee: Merck Patent Gesellschaft MIT
    Inventor: Berthold Nies
  • Patent number: 6123962
    Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula ##STR1## wherein R.sup.1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R.sup.2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R.sup.3 and R.sup.5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R.sup.4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.
    Type: Grant
    Filed: October 29, 1999
    Date of Patent: September 26, 2000
    Assignee: Takeda Chemical Industries, Inc.
    Inventors: Tadashi Makino, Tetsuro Tabata, Shin-Ichiro Hirai
  • Patent number: 6117868
    Abstract: A method and composition for the treatment of infectious gastrointestinal ulcer disease or infectious gastritis disease of microbially infected gastrointestinal tissue in a mammal involves administration of an antimicrobial amount of an antimicrobial medicament which is cell wall constituent-inactivating by chemical reaction with cell wall constituents, endotoxin non-releasing, exotoxin-inactivating or a combination thereof.
    Type: Grant
    Filed: May 20, 1999
    Date of Patent: September 12, 2000
    Assignee: Ed. Geistlich Sohne AG fur chemische Industrie
    Inventor: Rolf W. Pfirrmann
  • Patent number: 6110506
    Abstract: The present invention provides DASC compositions, which upon introduction into aqueous solutions, form stable, non-gritty suspensions. The present invention also provides stable, non-gritty suspensions comprising the DASC compositions of the present invention admixed in aqueous solutions. In addition, the present invention provides processes for preparing the suspensions which comprise admixing the DASC compositions of the present invention with aqueous solutions. Finally, the present invention provides processes for preparing the DASC compositions of the present invention.
    Type: Grant
    Filed: December 30, 1999
    Date of Patent: August 29, 2000
    Assignee: Chattem Chemicals, Inc.
    Inventors: Joel Swinson, Richard D. Giles, Jack Pitkin, Glenda Fleming, David B. Blum
  • Patent number: 6110891
    Abstract: This invention provides methods for: the control of mucosal cell proliferation; the reduction and/or treatment of damage caused by a cell-damaging agent; and for the reduction and/or treatment of a metabolic disorder.The methods comprise administering to an individual in need of control or reduction and/or treatment on effective amount of a lectin.The invention takes advantageous of the protective and repair capabilities of lectins. It is particularly useful in the prevention and treatment of animals undergoing radiotherapy and/or chemotherapy for cancer.
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: August 29, 2000
    Assignee: Alizyme Therapeutics Ltd.
    Inventors: Arpad Janos Pusztai, Zsuzsanna Magdolna Bardocz, Richard Michael John Palmer, Neil William Fish, Gyorgy J. Koteles
  • Patent number: 6086882
    Abstract: A phytochemical composition for management of peptic ulcer conditions in humans is provided. The composition is a hot water extract of powdered Indigofera arrecta plant leaves. The extract may be prepared by contacting the powdered leaves with hot water for a period of time, filtering the extraction mixture, concentrating the filtrate in vacuo and freeze drying the concentrated filtrate. The extract is admixed with magnesium carbonate, dried maize starch, talc and magnesium stearate to form a homogenous mass which is filled into capsules. The capsules are ingested orally to provide an analgesic effect. Also described are methods for making the extract and the methodology for using the extract.
    Type: Grant
    Filed: August 6, 1997
    Date of Patent: July 11, 2000
    Assignee: National Institute for Pharmaceutical Research
    Inventors: Charles O. N. Wambebe, Shingu K. Gamaniel, Peter Akah, Dogara S. Fumen, Hafsatu Shittu
  • Patent number: 6083509
    Abstract: A phytochemical composition for management of peptic ulcer conditions in humans is provided. The composition is a hot water extract of powdered Indigofera arrecta plant leaves. The extract may be prepared by contacting the powdered leaves with hot water for a period of time, filtering the extraction mixture, concentrating the filtrate in vacuo and freeze drying the concentrated filtrate. The extract is admixed with magnesium carbonate, dried maize starch, talc and magnesium stearate to form a homogenous mass which is filled into capsules. The capsules are ingested orally to provide an analgesic effect. Also described are methods for making the extract and the methodology for using the extract.
    Type: Grant
    Filed: January 11, 1999
    Date of Patent: July 4, 2000
    Assignee: National Institute for Pharmaceutical Research and Development
    Inventors: Charles O. N. Wambebe, Shingu K. Gamaniel, Peter Akah, Dogara S. Fumen, Hafsatu Shittu
  • Patent number: 6048552
    Abstract: The present invention provides DASC compositions, which upon introduction into aqueous solutions, form stable, non-gritty suspensions. The present invention also provides stable, non-gritty suspensions comprising the DASC compositions of the present invention admixed in aqueous solutions. In addition, the present invention provides processes for preparing the suspensions which comprise admixing the DASC compositions of the present invention with aqueous solutions. Finally, the present invention provides processes for preparing the DASC compositions of the present invention.
    Type: Grant
    Filed: March 26, 1997
    Date of Patent: April 11, 2000
    Assignee: Chattem Chemicals, Inc.
    Inventors: Joel Swinson, Richard D. Giles, Jack Pitkin, Glenda Fleming, David B. Blum
  • Patent number: 6043243
    Abstract: A pyrrolidine derivative or a salt thereof expressed by the following formula 1: ##STR1## wherein R.sub.1 is an alkenyl group; R.sub.2 is a lower alkoxy group or a halogen atom;R.sub.3 is a lower alkyl group;X is a group expressed by --O-- or --S--;Y is carbon or nitrogen atom;m is an integer of 1 to 3; andn is an integer of 0 to 2.The pyrrolidine derivative has an anti-ulcer effect or an antibacterial activity against Helicobacter pyroli, and has also high safety to be available for prevention or cure of ulcers.
    Type: Grant
    Filed: December 3, 1998
    Date of Patent: March 28, 2000
    Assignee: Shiseido Co., Ltd.
    Inventors: Chikao Nishino, Tomohiro Uetake
  • Patent number: 6013680
    Abstract: To provide a medicament that can be used as a drug for the effective treatment of gastric ulcers, duodenal ulcers and like diseases of the digestive tract. The medicament comprises a combination of at least one agent selected from the group consisting of histamine H.sub.2 receptor antagonists and proton pump inhibitors, and a digestive enzyme.
    Type: Grant
    Filed: October 21, 1998
    Date of Patent: January 11, 2000
    Assignee: Amano Pharmaceutical Co., Ltd.
    Inventors: Tomonari Ogawa, Kinya Kariya, Susumu Okabe
  • Patent number: 6013674
    Abstract: This invention provides novel indenone derivatives, their pharmaceutical formulations and their use for the inhibition of leukocyte adherence to cells.
    Type: Grant
    Filed: May 1, 1998
    Date of Patent: January 11, 2000
    Assignee: Eli Lilly and Company
    Inventors: John Michael Morin, Jr., Michael Dean Kinnick, Robert Theodore Vasileff, William Thomas Jackson
  • Patent number: 5935998
    Abstract: Use of compounds of formula (I), wherein R has various significances, in free base form or in pharmaceutically acceptable salt form, as agents against H. pylori infection and associated diseases.
    Type: Grant
    Filed: January 6, 1998
    Date of Patent: August 10, 1999
    Assignee: Novartis AG
    Inventors: Ivan James Dalton Lindley, Neil Stewart Ryder
  • Patent number: 5919824
    Abstract: Aminophenol derivatives represented by the following formula (1): ##STR1## wherein X is O or S; A is alkylene, R.sup.1 is phenyl, etc., R.sup.2 and R.sup.3 are H or alkyl; R.sup.4 is substituted carbamoylalkyl, etc.; R.sup.5 is substituted amino, etc.; their salts, and optical isomers of the derivatives and salts. Also disclosed are gastrin receptor antagonists, cholecystokinin receptor antagonists, and medicines for digestive diseases. The compounds have strong binding inhibition against gastrin receptor or CCK-A receptor and also they have higher selectivity to either group of CCK-A receptor or gastrin receptor, and therefore, the compounds are useful for preventing and treating gastrointestinal diseases including peptic ulcers as well as central nervous system diseases.
    Type: Grant
    Filed: September 12, 1997
    Date of Patent: July 6, 1999
    Assignee: Daiichi Pharmaceutical Co., Ltd.
    Inventors: Shuichi Yokohama, Keiichi Kawagoe, Yasuyuki Takeda, Yoshihiro Yokomizo, Aki Yokomizo
  • Patent number: 5914135
    Abstract: Calcium carbonate liquid antacid compositions containing one or more pH adjusting agents to maintain the pH above 9.0, preferably above 9.5. The resultant antacid liquid possesses superior resistance to microbial attack and enhanced taste properties.
    Type: Grant
    Filed: April 16, 1997
    Date of Patent: June 22, 1999
    Assignee: McNeil-PPC, Inc.
    Inventors: John J. Dubek, Gerard P. McNally, Bruce P. Smith
  • Patent number: 5900413
    Abstract: An infection with Helicobacter may successfully be treated with a compound of the formula ##STR1## wherein R.sub.1 is hydrogen or methyl and R.sub.2 is hydrogen or L-alanine-L-alanyl, and the pharmaceutically acceptable acid additive salts thereof. These compounds are useful in the treatment of gastric and duodenal ulcers.
    Type: Grant
    Filed: January 13, 1998
    Date of Patent: May 4, 1999
    Assignee: Pfizer Inc.
    Inventors: Arthur E. Girard, Thomas D. Gootz
  • Patent number: 5885960
    Abstract: The invention relates to active substance combinations which consist of at least one polypeptide with the biological action of fibroblast growth factors and of at least one cationic polyelectrolyte. These combinations permit improved dosage of the FGF activity. The invention also relates to a method of treating wounds, burns, skin ulcers, diabetic gangrene, mucosal ulcers and lesions, skin donation and transplantation sites, or surgical wounds by administering a peptide having FGF activity with an amount of cationic polyelectrolyte which is effective to decrease non-specific binding of the peptide having FGF activity.
    Type: Grant
    Filed: October 28, 1994
    Date of Patent: March 23, 1999
    Assignee: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventor: Berthold Nies
  • Patent number: 5879708
    Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula ##STR1## wherein R.sup.1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R.sup.2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R.sup.3 and R.sup.5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R.sup.4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.
    Type: Grant
    Filed: February 27, 1997
    Date of Patent: March 9, 1999
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Tadashi Makino, Tetsuro Tabata, Shin-Ichiro Hirai
  • Patent number: 5877192
    Abstract: A method for treatment of gastric acid related diseases by inhibition of gastric acid secretion comprising administering to a mammal in need of treatment a therapeutically effective amount of the (-)-enantiomer of 5-methoxy-2-??(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl!sulfinyl!-1H-benz imidazole or a pharmaceutically acceptable salt thereof, so as to effect decreased interindividual variation in plasma levels upon administration. The use of the (-)-enantiomer of omeprazole to receive increased average plasma levels (AUC) upon administration of the same doses of the (-)-enantiomer of omeprazole compared to those of racemic omeprazole is also claimed, as well as an improved antisecretory effect and a better clinical effect.
    Type: Grant
    Filed: April 11, 1997
    Date of Patent: March 2, 1999
    Assignee: Astra Aktiebolag
    Inventors: Per Lindberg, Lars Weidolf
  • Patent number: 5871774
    Abstract: Medical materials for use in treating maladies in living beings, such as ulcers and other conditions of the digestive tract. In one form, a container is provided for a medication which container also contains an adhesive material which is operatively released from the container or exposed at the surface thereof upon biodegradation or dissolution of a protective coating or wall portion of the container under the effects of fluid in the digestive tract in which the container is exposed, such as by swallowing, to permit such adhesive to temporarily bond and retain the container at a select location in the digestive tract so that it may slowly release its contents thereafter to a select portion of the digestive tract. In another form, a multitude of microcapsules, each containing a small quantity of medication, is mixed with an adhesive material, such as a sulcralfate other material which may be swallowed as a tablet or dissolved in a liquid such as water.
    Type: Grant
    Filed: October 28, 1993
    Date of Patent: February 16, 1999
    Inventor: Jerome H. Lemelson
  • Patent number: 5858365
    Abstract: This invention is directed to methods of administering physiologically stable and safe compositions of butyric acid salts and derivatives to a patient for the purpose of wound healing.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 12, 1999
    Assignee: Trustees of Boston University
    Inventor: Douglas V Faller
  • Patent number: 5852004
    Abstract: Use of at least one polymer or one biopolymer, called HBGFPPs, specifically protecting the growth factors of families of FGFs and beta TGFs from tryptic degradation and not significantly inhibiting coagulation, in the manufacture of a drug for the treatment of lesions of the digestive tract and of primary or secondary derived tissues of the endoderm and the mesoderm.
    Type: Grant
    Filed: December 30, 1996
    Date of Patent: December 22, 1998
    Assignee: Societe Valbiofrance
    Inventors: Denis Barritault, Jean-Pierre Caruelle, Anne Meddahi
  • Patent number: 5837240
    Abstract: Methods and compositions are provided for prophylactic and antibacterial therapy for Helicobacter, particularly for Helicobacter pylori, infection of humans. The immunogenic composition of the invention is composed of a plurality of multimeric complexes, each complex being composed of recombinant, enzymatically inactive Helicobacter pylori urease. Each multimeric complex is composed of six Urease A subunits and six Urease B subunits. Alternatively, the composition is composed of a mixture of multimeric complexes, wherein each multimeric complex in the mixture is composed of six Urease A subunits and six Urease B subunits or four Urease A subunits and four Urease B subunits.
    Type: Grant
    Filed: August 26, 1997
    Date of Patent: November 17, 1998
    Assignee: OraVax-Merieux Co.
    Inventors: Cynthia K. Lee, Thomas P. Monath, Samuel K. Ackerman, William D. Thomas, Gopalan Soman, Harold Kleanthous, Richard A. Weltzin, Jacques Pappo, Thomas Ermak, Farshad Guirakhoo, Hitesh Bhagat, Ilene Sussman